First patient treated in Clarity Pharmaceuticals’ copper-64 SARTATE Phase II trial in patients with neuroendocrine tumours (NETs)
Sydney, Australia 15 April 2021 – Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company focused on the treatment of serious disease, is pleased to announce that the first patient has been treated in the Phase II DISCO trial (Diagnostic Imaging Study of Copper-64 SARTATE™ Using PET on Patients With Known or Suspected Neuroendocrine Tumors). The DISCO…